Sign in

You're signed outSign in or to get full access.

AT

Adaptimmune Therapeutics PLC (ADAP)·Q3 2020 Earnings Summary

Executive Summary

  • Q3 revenue was $1.193M vs $0.237M in Q3 2019 (+403% YoY); net loss was $35.4M with EPS of $(0.04) per ordinary share. Cash was $78.5M and Total Liquidity $399.9M; guidance confirmed: funded into 2022 .
  • Clinical catalysts: SURPASS dose-escalation safety/response data slated for SITC; synovial sarcoma durability data at CTOS; Phase 2 initiation for ADP‑A2M4CD8 in gastroesophageal cancers targeted for 1H 2021; Investor Day on Nov 20, 2020 .
  • Enrollment recovering post COVID-19; SPEARHEAD‑1 recruiting well and on target for enrollment completion in 1H 2021, underpinning ambition to launch ADP‑A2M4 in the U.S. in 2022 .
  • Estimate comparison unavailable: S&P Global consensus data was not retrievable during this request; thus beats/misses vs Street cannot be evaluated (values unavailable via S&P Global).

What Went Well and What Went Wrong

What Went Well

  • Liquidity and runway: Total Liquidity of $399.9M and explicit guidance that operations are funded into 2022; Q3 cash and equivalents at $78.5M .
  • Clinical momentum: Management stated “ADP‑A2M4CD8 is a highly active agent across a range of tumors,” with initial tumor reductions in 5/6 SURPASS patients to be shown at SITC and plan to initiate Phase 2 in gastroesophageal cancers in 1H 2021 .
  • Enrollment improvement: “Recruitment into our clinical trials has been steadily recovering following the first wave of COVID‑19,” with SPEARHEAD‑1 on track for 1H 2021 completion; Investor Day set to outline a five-year strategy and late‑stage pipeline .

What Went Wrong

  • Minimal revenue base: Q3 revenue was $1.193M (still collaboration-driven) and net loss increased sequentially to $35.4M from $29.9M in Q2, reflecting higher operating loss and G&A spend for commercial build‑out .
  • COVID-19 headwinds continued to affect early-phase trials (site-by-site variation), delaying some recruitment and data timing despite improvements vs spring 2020 .
  • Operating intensity rising: Q3 G&A rose to $13.0M vs $10.3M in Q2 driven by professional fees, IT investments, and commercial capabilities, signaling higher opex ahead of launch preparation .

Financial Results

MetricQ3 2019Q1 2020Q2 2020Q3 2020
Revenue ($USD Millions)$0.237 $0.761 $0.502 $1.193
Net Loss ($USD Millions)$39.302 $28.167 $29.880 $35.432
EPS ($USD per ordinary share)$(0.06) $(0.04) $(0.04) $(0.04)
  • YoY: Revenue rose to $1.193M from $0.237M (+403%); net loss improved vs $39.3M in Q3 2019; EPS improved from $(0.06) to $(0.04) .
  • QoQ: Revenue increased vs $0.502M in Q2; net loss widened to $35.4M from $29.9M; EPS remained $(0.04) .

Operating detail and KPIs:

KPIQ1 2020Q2 2020Q3 2020
Cash and Cash Equivalents ($USD Millions)$86.4 $122.4 $78.5
Total Liquidity ($USD Millions)$196.4 $419.0 $399.9
R&D Expense ($USD Millions)$21.3 $20.5 $24.1
G&A Expense ($USD Millions)$9.3 $10.3 $13.0
Operating Loss ($USD Millions)$29.764 $30.253 $35.875
Weighted Avg Shares (Millions)739.8 822.7 928.0

Revenue composition (collaboration/licensing):

Revenue LineQ1 2020Q2 2020Q3 2020
Collaboration/Licensing ($USD Millions)$0.761 $0.502 $1.193

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Liquidity RunwayQ1 2020Funded into 2H 2021 ——
Liquidity RunwayQ2 2020Funded into 2022 —Raised vs Q1
Liquidity RunwayQ3 2020—Funded into 2022 (confirmed) Maintained vs Q2
Phase 2 ADP‑A2M4CD8 (GEJ) StartQ2 2020Protocol design underway; initiate 1H 2021 ——
Phase 2 ADP‑A2M4CD8 (GEJ) StartQ3 2020—On track to start 1H 2021 Maintained
SPEARHEAD‑1 EnrollmentQ3 2020—Complete enrollment 1H 2021 New specific timing

Earnings Call Themes & Trends

TopicQ1 2020 (May)Q2 2020 (Aug)Q3 2020 (Nov)Trend
COVID‑19 clinical impactEarly pandemic curtailed screening; expecting updates at ASCO/EASL; cautious on timelines Marked cutback in March/April; variable by region/site; SPEARHEAD‑1 screening met projections Enrollment improved across early-phase trials; SPEARHEAD‑1 less affected; recruiting well Improving but uneven; pivotal trial resilient
Manufacturing & vectorBuilding Navy Yard capacity; autologous focus; allogeneic R&D progress In‑house GMP vector use later in year; electronic systems optimizing costs; expanding capacity Continued manufacturing execution to support trials; confidence in CMC teams Scaling and insourcing to lower COGS
Regulatory/LegalEU ODD positive opinion for ADP‑A2M4; U.S. RMAT/ODD reiterated EMA PRIME support granted for ADP‑A2M4 in synovial sarcoma Focus on path to U.S. launch in 2022; SPEARHEAD‑1 timing Strengthening regulatory positioning
R&D execution (pipeline)Plan updates across ADP‑A2M4 (Phase 1), ADP‑A2AFP, radiation sub‑study; SURPASS initiated Responses across multiple tumors; plan new Phase 2 (GEJ); head & neck combo trial initiated SURPASS dose‑escalation update at SITC; synovial sarcoma durability at CTOS; GEJ Phase 2 plan Advancing from signals to Phase 2
Allogeneic platform (hiPSC)Demonstrated iPSC‑derived T‑cells; defined locus knock‑in; Astellas HiT target agreed First Astellas HiT program moving forward; target undisclosed; pipeline prioritization ongoing Program on track; timing to be discussed at Investor Day Strategic, medium‑term value driver
Combination therapy (pembro)Announced SPEARHEAD‑2 design forthcoming Trial-in-progress at ESMO; sequencing first‑line pembro with cell therapy upon non-response Clarified Phase 2 GEJ scope; continuing basket in Phase 1 for other tumors Defined sequencing strategy; expansion in GI

Management Commentary

  • “ADP‑A2M4CD8 is a highly active agent across a range of tumors… At CTOS, we will present data regarding the durability of responses in synovial sarcoma, which support our ambition to market ADP‑A2M4 in 2022.” — Adrian Rawcliffe, CEO .
  • “We will… show a compelling waterfall plot, with initial tumor reductions in five out of these six patients… indicative… of what is likely to be a highly active product.” — Elliot Norry, CMO, on SURPASS .
  • “Recruitment into our clinical trials has been steadily recovering… projected patient numbers currently look good for the remainder of this year and into 2021.” — Adrian Rawcliffe, CEO .
  • “We plan to initiate a Phase 2 trial in the first half of 2021 for… gastroesophageal cancers.” — Elliot Norry, CMO .

Q&A Highlights

  • Scope and timing: Phase 2 ADP‑A2M4CD8 will focus on gastroesophageal cancers; basket approach remains in Phase 1 (head & neck, bladder, lung, GEJ) with Phase 2 start targeted for 2021 .
  • SURPASS signal: Multiple initial tumor reductions; early unconfirmed PR dynamics clarified; additional patient to be presented at SITC; translational data on potency to be shown .
  • Pembrolizumab sequencing: Strategy to screen and begin pembro, then add cell therapy upon lack of clinical benefit, continuing pembro throughout; designed for rapid sequencing to minimize delays .
  • Allogeneic/HiT update: Astellas HiT program progressing; target undisclosed; broader allogeneic platform update expected at Investor Day .
  • Manufacturing/COGS: In‑house GMP vector expected to reduce COGS; electronic systems to improve operational efficiency .

Estimates Context

  • S&P Global consensus estimates for Q3 2020 and prior quarters were unavailable during this request; consequently, we cannot compare reported revenue/EPS vs Street forecasts or assess beats/misses. Where relevant, we note results without estimate comparison (consensus unavailable via S&P Global).

Key Takeaways for Investors

  • Near-term catalysts: SITC (SURPASS dose-escalation update), CTOS (synovial sarcoma durability), and Nov 20 Investor Day are likely stock movers; monitor GI tumor data and sarcoma durability signals .
  • Path to first launch: SPEARHEAD‑1 enrollment pacing supports 2022 U.S. launch ambition for ADP‑A2M4 in synovial sarcoma; regulatory momentum (EMA PRIME) reinforces potential .
  • Expanding into GI: Strong early signal in gastroesophageal cancers positions ADP‑A2M4CD8 for Phase 2 in 1H 2021; this broadens addressable market beyond sarcoma .
  • Balance sheet strength: $399.9M Total Liquidity and guidance funded into 2022 reduce financing risk near term, enabling execution across pivotal and Phase 2 programs .
  • Operating spend trajectory: G&A rising with commercial build‑out; expect continued investment ahead of launch; watch opex discipline as trials expand .
  • COVID‑19 watch: While enrollment improved, site variability persists; timelines in early-phase programs remain sensitive to regional pandemic dynamics .
  • Allogeneic optionality: The HiT/allogeneic platform could be a medium‑term catalyst; look for clarity at Investor Day on timelines and target disclosures .